Longevity & AgingOne CRISPR Injection May Permanently Lower LDL and Slash Heart Disease Risk
A next-generation gene-editing therapy called VERVE-102 uses base editing — a precise cousin of CRISPR — to permanently silence the PCSK9 gene in the liver, slashing LDL cholesterol by making a one-time, targeted DNA change. In clinical trials, a single dose reduced PCSK9 levels by 88%. Unlike traditional CRISPR, base editing doesn't cut both DNA strands, reducing the risk of dangerous large deletions. The science builds on decades of evidence: optimal LDL sits at 50–70 mg/dL, people born with broken PCSK9 genes have dramatically lower heart disease rates, and Mendelian randomization studies show lower LDL extends lifespan. While safety questions remain — including a patient death in a related Intellia trial — the VERVE-102 Heart-2 NEJM results are generating enormous excitement in cardiovascular medicine.
